Cambridge Antibody, Scil Proteins enter cross-license agreement

By Lisa Kerner

Charlotte, N.C., July 19 - Cambridge Antibody Technology and Scil Proteins GmbH entered into a cross-license agreement to research and develop therapeutic, diagnostic and technical products.

Under the deal, Cambridge Antibody obtains access to Scil Proteins' proprietary scaffold technology, Affilin, in the field of therapeutic indications.

Scil Proteins gains rights to Cambridge Antibody's ribosome display intellectual property to create and commercialize an unlimited number of Affilin-derived recombinant proteins for therapeutic, diagnostic and technical applications.

"The agreement underscores the enormous potential of alternative non-immunoglobulin derived binding proteins, such as our Affilin molecules for the development of novel targeted biotherapeutics," Scil Proteins managing director Ulrike Fiedler said in a company news release.

Cambridge Antibody, a subsidiary of AstraZeneca, is a biopharmaceutical company located in Cambridge, United Kingdom.

Scil Proteins is a biotechnology company located in Halle, Germany.

© 2015 Prospect News.
All content on this website is protected by copyright law in the U.S. and elsewhere. For the use of the person downloading only.
Redistribution and copying are prohibited by law without written permission in advance from Prospect News.
Redistribution or copying includes e-mailing, printing multiple copies or any other form of reproduction.